Survodutide — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Survodutide

Also known as: BI 456906, GCGR/GLP-1R dual agonist, glucagon receptor/GLP-1 receptor dual agonist

Dual glucagon receptor (GCGR) / glucagon-like peptide-1 receptor (GLP-1R) agonist; investigational peptide therapeutic

Research chemicalLast updated: October 31, 2026Based on 19 peer-reviewed studies

What it is

Survodutide is an investigational weight-loss drug in Phase 3 clinical trials for obesity and metabolic liver disease. It activates two hormone pathways to cut appetite and increase fat burning. Not FDA-approved; Phase 3 trials ongoing; showing strong results in liver fibrosis and weight reduction.

The scientific side

Survodutide (BI 456906) is a 29-amino acid peptide derived from glucagon that acts as a dual agonist at both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). It contains a C18 diacid moiety that mediates binding to albumin, prolonging its half-life to enable once-weekly subcutaneous dosing. GLP-1R agonism suppresses appetite and stimulates insulin secretion, while GCGR agonism aims to enhance body-weight-lowering effects by increasing energy expenditure and stimulating hepatic lipolysis and mitochondrial fat oxidation. Preclinically, survodutide demonstrated body weight-lowering efficacy through decreased energy intake and increased energy expenditure. In the central nervous system, survodutide accesses circumventricular organs (CVOs) and adjacent hypothalamic and hindbrain nuclei without uniformly crossing the blood-brain barrier; c-Fos labeling showed activation of multiple nuclei associated with control of food intake, with the intake-suppressive effects being GLP-1R-dependent. The natural gut hormone oxyntomodulin is a weak dual GCGR/GLP-1R agonist; survodutide was developed to mimic and potentiate this mechanism. Regarding liver effects, mediation analysis in a MASH phase 2 trial indicated that endpoints related to improvements in inflammation and fibrosis were predominantly weight-reduction-independent, suggesting a potential direct role of glucagon receptor agonism in the liver.

Class: Dual glucagon receptor (GCGR) / glucagon-like peptide-1 receptor (GLP-1R) agonist; investigational peptide therapeutic

Administration & storage

Administration
Subcutaneous injectiononce weekly (PMID: 42253238)Subcutaneous injectiononce weekly (PMID: 38330987)Subcutaneous injectiononce weekly (PMID: 38847460)Subcutaneous injectiononce weekly (PMID: 42252333)Subcutaneous injectiononce weekly or twice weekly (PMID: 38095657)Subcutaneous injectionsingle dose and multiple doses (PMID: 38857788)
Storage
Storage conditions for survodutide are not described in the reviewed abstracts.
Cautions
Gastrointestinal adverse events (nausea, vomiting, diarrhea) are the most common class effects, occurring in approximately 75-90% of survodutide-treated participants in clinical trials, typically during dose escalation, and are generally mild to moderate (PMID: 42253238, PMID: 38847460, PMID: 38330987).,Survodutide is an investigational drug and is not approved by any regulatory authority reviewed in the available literature; it should only be used within the context of authorized clinical trials.,In a phase 1 trial in people with cirrhosis, drug-related adverse events occurred in up to 87.5% of cirrhotic participants during multi-dose escalation to 6.0 mg; careful monitoring is warranted in hepatically impaired populations.,Preliminary data suggest survodutide may increase heart rate to a similar extent as GLP-1 receptor monoagonists; cardiovascular safety is being evaluated in the ongoing SYNCHRONIZE-CVOT trial (PMID: 42535526, PMID: 39453356).,Higher doses of survodutide (>2.4 mg/week) were associated with a higher risk of treatment discontinuation due to gastrointestinal adverse events; dose escalation rate may mitigate gastrointestinal adverse events (PMID: 40922121, PMID: 38095657).,Sterile technique is essential for subcutaneous self-injection to prevent injection-site infection (universal caution, no specific PMID required).

Legal & regulatory status

US FDA

Not approved; investigational drug under phase 3 clinical development (PMID: 42253238, PMID: 42252333). Not stated as approved in reviewed literature — requires manual verification.

WADA

Not stated in reviewed literature — requires manual verification.

Health Canada

Not stated in reviewed literature — requires manual verification.